使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to the Align Technology Second Quarter Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.
各位好,歡迎參加 Align Technology 第二季財報電話會議。(接線員指示)提醒您,本次會議將被錄音。
It is now my pleasure to introduce your host, Shirley Stacy, Vice President, Corporate and Investor Communications. Thank you. You may begin.
現在很榮幸為各位介紹本次會議主持人:企業與投資人溝通副總裁 Shirley Stacy。謝謝。您可以開始了。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Thank you, everyone, and thank you for joining us. Joining me today is Joe Hogan, President and CEO; and John Morici, CFO. We issued second quarter 2020 financial results today via GlobeNewswire, which is available on our website at investor.aligntech.com. On April 1, 2020, we completed the acquisition of privately held exocad Global Holdings GmbH (exocad). To reflect this addition of exocad into our operations as of Q2 '20, we have renamed the Scanner and Services segment to Imaging Systems & CAD/CAM Services or Systems and Services.
謝謝各位,也感謝大家加入我們。今天與我一同出席的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。我們今天已透過 GlobeNewswire 發布 2020 年第二季財務結果,您可至 investor.aligntech.com 查閱。2020 年 4 月 1 日,我們完成收購私人持有的 exocad Global Holdings GmbH(exocad)。為反映自 2020 年第二季起將 exocad 納入營運,我們已將「掃描器與服務」事業部更名為「影像系統與 CAD/CAM 服務」(Imaging Systems & CAD/CAM Services),或簡稱「系統與服務」。
Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on August 5. To access the telephone replay, domestic callers should dial (877) 660-6853, with conference number 13705887, followed by #. International callers should dial (201) 612-7415, with the same conference number.
今天的電話會議將以音訊網路直播,並在我們網站上封存約 1 個月。電話重播將於今日美東時間約下午 5:30 起提供,至 8 月 5 日美東時間下午 5:30 止。若要收聽電話重播,美國境內來電者請撥打 (877) 660-6853,會議號碼 13705887,然後按 #。國際來電者請撥打 (201) 612-7415,會議號碼相同。
As a reminder, the information provided and discussed today will include forward-looking statements, including statements about Align's future events and product outlook. These forward-looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and at sec.gov. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statement.
提醒各位,今天提供與討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件與產品展望的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近向美國證券交易委員會(SEC)提交的定期報告中有更詳細說明,您可於我們網站及 sec.gov 查閱。實際結果可能有重大差異,Align 明確表示不負有更新任何前瞻性陳述之義務。
We have posted historical financials, including the corresponding reconciliations, including our GAAP to non-GAAP reconciliation, as applicable. And our second quarter 2020 conference call slides are on our website under Quarterly Results. Please refer to these files for more detailed information.
我們已發布歷史財務資料(含相對應之調節表),包括適用時的 GAAP 與非 GAAP 調節。此外,我們的 2020 年第二季電話會議簡報已上傳至網站「Quarterly Results」專區。請參閱這些檔案以取得更詳細資訊。
And with that, I'd like to turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我想把電話交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, Shirley. Good afternoon, and thanks for joining us. I'm pleased to report Q2 results and continued progress across all regions and customer channels that reflect our COVID-19 recovery efforts and those of our customers.
謝謝,Shirley。各位下午好,感謝加入我們。我很高興報告第二季的業績,以及我們在所有地區與客戶通路持續取得的進展,這些都反映了我們與客戶為 COVID-19 復甦所做的努力。
Practices across every region have reopened and are seeing patients, and many of those practices are embracing digital treatment in new ways and more purposely than ever before. In particular, Invisalign providers are using the virtual tools we expedited over the last few months to minimize in-office appointments and deliver doctor-directed personalized treatment that meets the needs of the moment, trusted, safe, convenient and reflecting the digital option. Initiatives we have prioritized globally over the last few months, including support for doctors to ensure treatment and business continuity, a shift to online education and training, ramping availability of virtual tools to keep doctors and patients connected throughout the treatment. And continued investment in consumer marketing, concierge programs and personal protective equipment or PPE are helping doctors navigate this evolving environment and come back stronger as their practices have reopened.
各地區的診所都已重新開放並開始看診,許多診所也以前所未有、更有目的性的方式採用數位化治療。特別是 Invisalign 供應商正在使用我們在過去幾個月加速推出的虛擬工具,以減少到診次數,並提供由醫師主導的個人化治療,以符合當下需求——值得信賴、安全、便利,並體現數位選項。我們過去幾個月在全球優先推動的措施,包括支援醫師以確保治療與營運的持續性、轉向線上教育與訓練、提升虛擬工具的可用性以在整個療程中維持醫師與患者的連結,以及持續投入消費者行銷、禮賓(concierge)計畫與個人防護裝備(PPE),都在協助醫師因應這個不斷演變的環境,並在診所重新開放後更強勢地回歸。
We have received consistently positive reactions and feedback from doctors in support of our efforts over the last few months. While it's too early to know for sure how extensive and sustainable the digital transition will be, interest in digital solutions is building, even among doctors who are not early adopters or advocates prior to the pandemic. The positive feedback and momentum is not just around Invisalign treatment. It includes digital workflow around iTero scanners and general dentistry. Doctors are telling us that iTero is central to their practice and to their practice workflows, and it's key to driving digital treatment.
過去幾個月,我們持續收到醫師對我們努力的正面反應與回饋。雖然現在仍言之過早,尚無法確定數位轉型的規模與可持續性,但對數位解決方案的興趣正在升溫,甚至包括在疫情前並非早期採用者或倡議者的醫師。這股正向回饋與動能不僅圍繞 Invisalign 治療,也涵蓋 iTero 掃描器與一般牙科的數位工作流程。醫師告訴我們,iTero 是其診所與工作流程的核心,也是推動數位化治療的關鍵。
With that, let me turn to results. For Q2, total revenues were $352 million, down 36% sequentially and down 41% year-over-year, reflecting significantly lower sales of Invisalign clear aligners and iTero scanners due to a full quarter's effect of COVID-19 pandemic on practice closures. Revenues from clear aligners were $298 million, and Imaging Systems & CAD/CAM Services were $54 million.
接下來談業績。第二季總營收為 3.52 億美元,較前一季下降 36%,較去年同期下降 41%,主要反映因 COVID-19 疫情導致診所關閉整整一季,使 Invisalign 隱形矯正器與 iTero 掃描器銷售大幅下滑。隱形矯正器營收為 2.98 億美元;影像系統與 CAD/CAM 服務營收為 5,400 萬美元。
On a year-over-year basis, while clear aligner shipments were 222,000 cases, down 41% year-over-year, we are pleased with the continued progress we've seen from our recovery efforts throughout the quarter. For the quarter, we shipped Invisalign cases to approximately 48,000 doctors, of which 3,000 were first-time customers, reflecting lower doctor activity due to practice closures primarily in America's GP channel.
以年對年來看,雖然隱形矯正器出貨量為 222,000 例,較去年同期下降 41%,但我們對本季在復甦努力上所見到的持續進展感到滿意。本季我們向約 48,000 位醫師出貨 Invisalign 病例,其中 3,000 位為首次購買客戶,反映因診所關閉導致醫師活動降低,主要發生在美洲的一般牙科(GP)通路。
We also trained approximately 3,500 new doctors in Q2, including 2,350 international doctors. While our inability to hold in-person courses due to COVID-19 resulted in fewer trained doctors in the second quarter, we continue with a significantly larger number of Invisalign doctors through online virtual education courses, summits and forums. For the teen market in Q2, 71,000 teens and preteens started treatment with Invisalign clear aligners, representing 32% of total cases shipped, reflecting growth from APAC across comprehensive products. By the end of the quarter, we started to see recovery in the ortho channel with increases in Invisalign comprehensive treatments in the teens and preteens segment across most regions, with positive growth predominantly in APAC in the teen segment.
第二季我們也訓練了約 3,500 位新醫師,其中包括 2,350 位國際醫師。由於 COVID-19 使我們無法舉辦實體課程,第二季受訓醫師數較少;但我們仍透過線上虛擬教育課程、峰會與論壇,持續觸及顯著更多的 Invisalign 醫師。就第二季青少年市場而言,有 71,000 名青少年與學齡前青少年開始使用 Invisalign 隱形矯正器治療,占總出貨病例的 32%,反映亞太地區在全方位(comprehensive)產品上的成長。至本季末,我們開始看到矯正(ortho)通路的復甦:在多數地區,青少年與學齡前青少年族群的 Invisalign comprehensive 治療量增加;其中青少年族群的正成長主要來自亞太地區。
Invisalign First continues to accelerate among young patients as well and reflects greater resiliency as parents continue to prioritize orthodontic treatment for their kids. Overall, both noncomprehensive and comprehensive shipments were down, but with increased adoption of our moderate product among the ortho channel.
Invisalign First 在年幼患者中的成長也持續加速,並展現較高韌性,因為家長仍持續優先考量孩子的齒顎矯正治療。整體而言,非 comprehensive 與 comprehensive 的出貨量皆下降,但在矯正通路中,我們的中度(moderate)產品採用率有所提升。
Last week, we held our Teen Forum Virtual Edition, taking what was a popular teen intensive program for orthodontists launched last year and recreating it as a virtual experience. In order to facilitate broader attendance among our customer doctors, we scheduled 2 Teen Forum virtual events. The first took place on July 17, and the second will be held this Friday. The program is designed to help doctors understand the highly visible online and on-demand world of today's teens and provide the know-how, tools and confidence to differentiate and grow their Invisalign teen practices.
上週我們舉辦了 Teen Forum Virtual Edition,將去年推出、深受矯正醫師歡迎的青少年密集課程,重新打造為虛擬體驗。為了讓更多客戶醫師能參與,我們安排了兩場 Teen Forum 線上活動:第一場於 7 月 17 日舉行,第二場將於本週五舉行。此計畫旨在協助醫師了解當今青少年高度可見的線上與隨選世界,並提供專業知識、工具與信心,以建立差異化並成長其 Invisalign 青少年業務。
Approximately 800 customers have registered for this full-day session that combines live and on-demand sessions, clinical and practice integration presentations, panel discussions and invaluable insights from experts with successful teen practices.
約有 800 位客戶已註冊參加這場全天課程,內容結合即時與隨選場次、臨床與診所整合簡報、座談討論,以及來自擁有成功青少年業務之專家的寶貴洞見。
Now let's turn to the specifics around our second quarter results, starting with the Americas. For the Americas region, Q2 Invisalign case volume was down 53% sequentially and down 52% year-over-year, reflecting significantly fewer Invisalign case shipments due to the impact of COVID-19. For Q2, reported utilization was down for NA orthos and GPs, both quarter-over-quarter and year-over-year. However, utilization increased in June, especially among certain orthodontists doing more Invisalign treatments with teen shipments recovering faster in North America in late May and through June. As part of our recovery programs, we enable doctors to switch their braces patients into Invisalign treatment by buying their wires and brackets. This program was well received, and as a result, doctors converted approximately 2,500 wires and bracket cases to Invisalign clear aligner patients.
現在我們來看第二季業績的細節,先從美洲開始。美洲地區第二季 Invisalign 病例量較前一季下降 53%,較去年同期下降 52%,反映 COVID-19 影響下 Invisalign 病例出貨顯著減少。第二季北美矯正醫師與一般牙科醫師(GP)的報告使用率(utilization)不論季對季或年對年皆下降。然而,6 月使用率有所回升,尤其是部分矯正醫師進行更多 Invisalign 治療;北美的青少年出貨在 5 月下旬至 6 月期間復甦更快。作為我們復甦計畫的一部分,我們讓醫師可透過購買其鋼線與托槽,將原本使用傳統牙套的患者轉換為 Invisalign 治療。此計畫反應良好,因此醫師約將 2,500 例鋼線與托槽病例轉換為 Invisalign 隱形矯正患者。
In the GP segment, the timing of office reopenings and case prioritization slowed the recovery in this key segment as compared to the orthodontic segment, but the GP segment is catching up. In terms of timing of the recovery in the Americas, the U.S. continues to lead, followed by Canada and then LATAM, corresponding to the timing of the pandemic-related shutdowns and reopenings in each region.
在一般牙科(GP)領域,診所重新開放的時點與病例優先順序,使這個關鍵領域的復甦相較矯正領域更慢,但 GP 領域正在追趕。就美洲復甦時程而言,美國仍領先,其次是加拿大,再來是拉丁美洲(LATAM),與各地區疫情相關的停業與重啟時點相一致。
For our international business, Q2 Invisalign case volumes were down 17.2% sequentially, reflecting a significant decrease in EMEA, again due to the impact of COVID-19, partially offset by growth from APAC, which is ahead in the recovery curve, in China, Taiwan, Hong Kong and South Korea. On a year-over-year basis, international shipments were down 27.1%, reflecting a decline in EMEA, partially offset by slight growth in APAC. For EMEA, Q2 volumes were down sequentially 44% and down 46% on a year-over-year basis across all markets, with more softness in the GP channel compared to ortho. We continue to see momentum with Invisalign First for Invisalign treatment in young patients. Overall, we saw a slower deceleration in teen shipment growth than adults driven by Germany and France. The expansion markets had less decline and only accounted for 5 points of the decline in EMEA.
在國際業務方面,第二季 Invisalign 病例量較前一季下降 17.2%,反映 EMEA 顯著下滑(同樣受 COVID-19 影響),但部分被亞太地區的成長所抵銷;亞太在復甦曲線上領先,成長來自中國、台灣、香港與南韓。以年對年來看,國際出貨量下降 27.1%,反映 EMEA 下滑,部分被亞太的小幅成長所抵銷。就 EMEA 而言,第二季量能較前一季下降 44%,較去年同期下降 46%,涵蓋所有市場;其中 GP 通路的疲弱程度高於矯正通路。我們持續看到 Invisalign First 在年幼患者 Invisalign 治療上的動能。整體而言,我們看到青少年出貨成長的減速幅度小於成人,主要由德國與法國帶動。擴張市場的下滑較少,且僅占 EMEA 下滑中的 5 個百分點。
We also rolled out a Recovery 360 program in EMEA, with over 3,700 orthodontists enrolled, resulting in a stronger partnership perception by our customers, including an increase in our Net Promoter Score or NPS. Using a combination of our ADAPT consultants, which I'll be describing more later, and territory managers, we helped practices with their workflow and scheduling; increased our doctors' engagement with their patients through the use of education and communication tools; and provided business viability, access and sustainability materials to the doctors.
我們也在 EMEA 推出了 Recovery 360 計畫,已有超過 3,700 位矯正醫師加入,使客戶對我們的合作夥伴關係觀感更為強化,並帶動我們的淨推薦值(Net Promoter Score,NPS)提升。我們結合 ADAPT 顧問(我稍後會再更詳細說明)與區域經理,協助診所改善工作流程與排程;透過教育與溝通工具提升醫師與病患的互動與參與度;並向醫師提供有關業務可行性、可近性與永續性的相關資料。
In May, over 1,400 attendees from 3 regions, 75 countries participated in our virtual Invisalign Scientific Forum in EMEA. At the end of June, we held a virtual GP Growth Summit, with over 1,300 doctors from over 42 countries who signed up to gain insights on business, dentistry, health and change management. During the summit, we launched our GP Recovery Program and received great feedback on the tools and approach we provide to support business recovery. During the quarter, we also offered over 150 online and on-demand education events, which reached over 20,000 GPs cumulatively.
5 月,來自 3 個區域、75 個國家的 1,400 多名與會者參加了我們在 EMEA 舉辦的線上 Invisalign 科學論壇。6 月底,我們舉辦了線上 GP Growth Summit(全科醫師成長高峰會),有來自 42 個以上國家的 1,300 多位醫師報名,藉此獲取商業、牙科、健康與變革管理方面的洞見。峰會期間,我們推出 GP Recovery Program,並就我們提供以支援業務復甦的工具與方法獲得非常正面的回饋。本季我們也提供了超過 150 場線上與隨選教育活動,累計觸及超過 20,000 名全科醫師(GP)。
In July, we launched the Invisalign Go Plus system in the U.K., Nordic and Benelux, which offers wider treatment options, enables dentists to treat more patients with confidence and can be easily integrated into a wide range of restorative treatments in their practice. For APAC, Q2 volumes were up sequentially 41%, reflecting improving trends as practices reopened and got back to business as well as COVID-19 recovery measures we implemented in China. On a year-over-year basis, APAC was up 3.4% compared to the prior year and was the only region up year-on-year. As mentioned earlier, we saw positive growth in APAC in teen shipments, led by China, reflecting a strong uptick of recovery programs.
7 月,我們在英國、北歐與比荷盧推出 Invisalign Go Plus 系統,提供更廣泛的治療選項,使牙醫能更有信心地治療更多病患,並可輕鬆整合至診所多種修復治療中。就 APAC 而言,第二季出貨量較前一季成長 41%,反映診所重新開業並恢復營運的改善趨勢,以及我們在中國實施的 COVID-19 復甦措施。以年對年來看,APAC 較去年同期成長 3.4%,是唯一年對年成長的區域。如先前所述,我們在 APAC 的青少年出貨量呈現正成長,由中國帶動,反映復甦計畫帶來的強勁回升。
In the GP segment, we saw growth in the noncomprehensive cases with Invisalign Go and the launch of Moderate in China in March, continuing to further demonstrate doctor confidence in treating young patients with Invisalign. Throughout the region, Japan and Taiwan, South Korea successfully managed recovery efforts and performed better than expected.
在 GP(全科醫師)客群中,我們看到 Invisalign Go 的非全口(noncomprehensive)病例成長,以及 3 月在中國推出 Moderate 方案,持續進一步展現醫師對以 Invisalign 治療年輕病患的信心。在整個區域內,日本與台灣、南韓成功推動復甦工作,表現優於預期。
During the quarter, we reached another major milestone with our 1 millionth Invisalign patient in APAC, an athlete in modern pentathlon and fencing, who is being treated by Dr. Yokoya in Tokyo, Japan. Earlier this month, we held the Invisalign Teen Forum in China in a virtual forum broadcast to 4 venues in Beijing, Chengdu, Wuhan and Hangzhou, to approximately 8,000 participants. The forum focused on the innovations and applications of digital technology in clear aligners as well as theories and clinical practices for teen patients. The forum brought together outstanding orthodontists from leading dental colleges from approximately 30 academic institutions. We believe that our global clinical education programs are the best in the industry, and we have been even more valuable to the doctors throughout the pandemic.
本季我們在 APAC 達成另一項重大里程碑:迎來第 100 萬位 Invisalign 病患;該病患為現代五項與擊劍運動員,由日本東京的 Yokoya 醫師治療。本月稍早,我們在中國舉辦 Invisalign Teen Forum(青少年論壇),以線上形式同步轉播至北京、成都、武漢與杭州 4 個會場,約有 8,000 名參與者。論壇聚焦於數位技術在隱形矯正器的創新與應用,以及青少年病患的理論與臨床實務。論壇匯聚了約 30 所學術機構、頂尖牙科院校的傑出矯正醫師。我們相信,我們的全球臨床教育計畫是業界最佳;在疫情期間,我們對醫師的價值更為提升。
We launched a new and improved digital learning environment for our doctors this year, offering a comprehensive learning platform with role-specific content for orthos, GPs and their teams. The improved functionality enables more online learning opportunities, with spotlight features for what's trending now; recommending learning paths based on doctors' experiences; and expanded categories, including digital treatment planning, comprehensive dentistry and team education. To date, over 85,000 doctors have accessed recorded lectures and completed self-paced learning modules and watched how-to videos in over 3 million sessions. Among the ortho channel, over 30,000 unique users have engaged with a digital learning site, with an additional 50,000 unique users from the GP channel. We are encouraged by the digital training utilization rates among our doctors, which has helped them continue their Invisalign treatment learning journey during the pandemic. Feedback from the participants describes the courses as engaging, providing broader reach to online events and a strong desire that Align continue to provide these virtually. They also acknowledge Align's agility in providing relevant tools and content to help them during the lockdowns. We see this as an ongoing opportunity to enhance doctor learning through direct feedback and continuous improvement.
今年我們為醫師推出全新且升級的數位學習環境,提供一個完整的學習平台,並為矯正醫師(ortho)、全科醫師(GP)及其團隊提供依角色設計的內容。升級後的功能帶來更多線上學習機會,包括:聚焦目前熱門主題的精選功能;依醫師經驗推薦學習路徑;以及擴充的分類,涵蓋數位治療規劃、全方位牙科與團隊教育。迄今已有超過 85,000 位醫師存取錄製講座、完成自學模組,並在超過 300 萬次的使用場次中觀看教學影片。在矯正通路方面,超過 30,000 名不重複使用者參與數位學習網站;GP 通路另有 50,000 名不重複使用者。我們對醫師的數位訓練使用率感到鼓舞,這也幫助他們在疫情期間持續進行 Invisalign 治療的學習旅程。參與者回饋指出課程具吸引力、能擴大線上活動觸及範圍,並強烈希望 Align 能持續以線上方式提供。他們也肯定 Align 在封城期間能敏捷地提供相關工具與內容以協助他們。我們視此為一項持續的機會,可透過直接回饋與持續改善來強化醫師學習。
Building on the benefit of clinical education and training, today, we announced the global launch of the Align Digital and Practice Transformation or ADAPT service. This is our first customized consulting service and support offering for doctors and was developed based on years of learnings from practices that saw strong growth in practice transformation when changing their practice to digital. Initially available to Invisalign and iTero doctors in select segments of the EMEA market and then in the U.S., the global program is now generally available in EMEA and APAC regions and will be available in the U.S. in the second half of this year. The ADAPT program is an expert and independent fee-based business consulting service offered by Align to optimize clinics, operational workflow and processes to enhance patient experience and customer and staff satisfaction, which will in turn translate into higher growth and greater efficiencies for orthodontic practices.
在臨床教育與訓練效益的基礎上,我們今天宣布全球推出 Align Digital and Practice Transformation(ADAPT)服務。這是我們首項為醫師提供的客製化顧問服務與支援方案,係根據多年來的學習與經驗所開發,這些經驗來自於在將診所轉型為數位化後、於診所轉型方面實現強勁成長的診所。該服務最初在 EMEA 市場的特定細分領域提供給 Invisalign 與 iTero 醫師,之後在美國推出;目前此全球計畫已在 EMEA 與 APAC 地區普遍提供,並將於今年下半年在美國推出。ADAPT 計畫是 Align 提供的專家型、獨立且採收費制的商業顧問服務,旨在優化診所、營運工作流程與流程,以提升病患體驗以及客戶與員工滿意度,進而為矯正診所帶來更高的成長與更佳的效率。
The goal of the ADAPT program is to support digital practice transformation for doctors and their staff. ADAPT is designed for orthodontists with approximately 200 total case starts per year, who are seeking to build their future business. Driven by a team of independent business consultants, analysts and program support specialists, ADAPT offers a customized on-site consulting service to each participating practice. The program combines a review of business operations and practice workflow data with Align's expertise and digital workflow optimization, practice support, business transformation, marketing and clinical education support.
ADAPT 計畫的目標是支援醫師及其員工進行數位化診所轉型。ADAPT 專為每年約 200 例總開案數(case starts)的矯正醫師設計,協助其打造未來業務。ADAPT 由一支獨立的商業顧問、分析師與計畫支援專家團隊推動,為每一家參與診所提供客製化的到場顧問服務。該計畫結合對營運與診所工作流程數據的檢視,以及 Align 在專業與數位工作流程優化、診所支援、業務轉型、行銷與臨床教育支援方面的能力。
The pilot version of the program has been successfully developed across EMEA, the United States, Asia Pacific region over the last 12 months. As a result of the ADAPT service, participating practices improved profitability up to 15% within 6 months of implementation and increased practice revenue up to 20%.
在過去 12 個月中,該計畫的試行版本已在 EMEA、美國與亞太地區成功建立。導入 ADAPT 服務後,參與診所在實施後 6 個月內,獲利能力最高提升 15%,診所營收最高提升 20%。
Our consumer marketing is focused on building the clear aligner category and driving demand for Invisalign treatment through a doctor's office. In Q2, we saw strong digital engagement globally, with more than 70% increase in unique visitors as well on leads. Other key metrics showed increased activity engagement with the Invisalign brand and are included in our Q2 quarterly presentation slides available on our website.
我們的消費者行銷聚焦於建立隱形矯正器品類,並透過醫師診所推動 Invisalign 治療需求。第二季,我們在全球看到強勁的數位互動,獨立訪客數以及潛在客戶(leads)均增加超過 70%。其他關鍵指標亦顯示 Invisalign 品牌互動活動增加,相關內容已納入我們網站上提供的第二季季度簡報投影片中。
We're pleased with the strong engagement and activity we've seen on our customer platforms over the last few months and believe it speaks to the strength of the brand and consumer interest in treatment even during the challenges of the last few months. In Q3, we are coming into what is typically the strongest part of the teen season, when teens and younger kids are home for the summer break and likely to start treatment before heading back to school. And while back-to-school looks very different this year in many countries, including the United States, this is still a time when practices, especially orthodontic practices, are focusing on younger patients. Teens are the biggest and most critical part of orthodontic practices and are huge influencers and drivers of practice growth. That matters now more than ever as we partner with practices in this recovery.
我們對過去幾個月在客戶平台上看到的高度互動與活躍度感到滿意,並相信這反映了品牌的強勁力道,以及即使在過去幾個月的挑戰之下,消費者對治療仍具高度興趣。第三季通常進入青少年旺季中最強勁的時段:青少年與年幼孩童在暑假期間在家,較可能在返校前開始治療。儘管今年許多國家(包括美國)的返校情況大不相同,但這仍是診所、尤其是矯正診所,聚焦年輕病患的時期。青少年是矯正診所最大且最關鍵的族群,也是影響力極大、推動診所成長的重要驅動者。當我們在這次復甦中與診所攜手合作時,這一點比以往任何時候都更為重要。
One of the most important ways we partner with customers is by creating demand for Invisalign treatment and to drive teens and parents to their practices for great outcomes and great treatment experiences. We have just launched a new teen- and mom-focused consumer campaign designed to do this just that -- by reaching teens and moms where they are most engaged on digital platforms, social channels and later this year, national and cable TV channels, where they spend the most time, like Instagram, Twitch for teens; Instagram, Facebook and People.com from moms. We're going to leverage influencers that teams and kids follow and trust, like Charli D' Amelio. We recently established a new partnership with Charli, who is a really dynamic kid and accomplished dancer who has a combined following of over 90 million fans on TikTok and Instagram. She's about to become a new Invisalign patient and ambassador for our brand. She'll be sharing her treatment journey in a way that is relevant to teens across social platforms.
我們與客戶合作最重要的方式之一,是創造 Invisalign 治療需求,並將青少年與家長帶到其診所,以獲得優異成果與良好治療體驗。我們剛推出一項全新的、以青少年與媽媽為核心的消費者行銷活動,目的正是如此——在數位平台與社群渠道上觸及青少年與媽媽最投入的場域,並於今年稍晚擴展至全國性與有線電視頻道等他們花最多時間的媒體,例如青少年常用的 Instagram、Twitch;以及媽媽常用的 Instagram、Facebook 與 People.com。我們將運用青少年與孩子追蹤且信任的意見領袖(influencers),例如 Charli D' Amelio。我們近期與 Charli 建立新的合作夥伴關係;她是一位充滿活力且成就卓著的舞者,在 TikTok 與 Instagram 的合計追蹤者超過 9,000 萬。她即將成為新的 Invisalign 病患與品牌大使,並將以貼近青少年的方式,在各社群平台分享她的治療旅程。
And our new campaign will get the heart of what -- get to the heart of what Invisalign is and what it isn't, using straightforward language that teens respond to. Our goal is to tell teens why parents -- Invisalign is more advanced and more comfortable than traditional braces, emphasizing that this is not your parents' braces. We also want to ensure that they know that doctors are front and center in the Invisalign treatment because it's time to be very candid about the benefits of digital orthodontics and Invisalign treatment specifically.
而我們的新活動將以青少年能接受的直白語言,切入 Invisalign 的核心——它是什麼、以及它不是什麼。我們的目標是告訴青少年,為什麼家長——Invisalign 相較於傳統牙套更先進、更舒適,並強調這不是你父母那一代的牙套。我們也希望確保他們了解,在 Invisalign 治療中醫師始終是核心,因為現在是時候非常坦率地談論數位矯正與 Invisalign 治療本身的益處。
For our Systems and Services business, which now includes exocad, Q2 revenues were down 22% sequentially. We were pleased to see the momentum with Element 5D imaging systems in North America and APAC, along with sales of iTero Element 1 scanner model in China and significant sales of the Flex scanner model in EMEA. On a year-over-year basis, Systems and Services revenues were down 48%, were slightly offset by the inclusion of exocad CAD/CAM Services. Cumulative -- over 24 million orthodontic scans and 5.5 million restorative scans have been performed with iTero scanners.
就我們的系統與服務業務而言(現已納入 exocad),第二季營收較前一季下滑 22%。我們很高興看到 Element 5D 影像系統在北美與亞太地區(APAC)的成長動能,同時也看到 iTero Element 1 掃描儀機型在中國的銷售,以及 Flex 掃描儀機型在歐洲、中東與非洲(EMEA)的顯著銷售。以年對年來看,系統與服務營收下滑 48%,但因納入 exocad CAD/CAM 服務而略有抵銷。累計而言——已透過 iTero 掃描儀完成超過 2,400 萬次矯正掃描與 550 萬次修復掃描。
For Q2, total Invisalign cases submitted with a digital scanner in the Americas increased to 86% from 77% in Q2 last year. International scans increased to 72%, up from 61% in the same quarter last year. We're pleased to see that within the Americas, 96% of cases submitted by North American orthodontists were submitted digitally. We also recently announced that the iTero Element 5D imaging system was awarded Best New Technology Solution for Dentistry in the 2020 MedTech Breakthrough Awards. The annual program honors outstanding health and medical technology products and companies. We also received an award from DentistryIQ, naming the iTero Element 5D imaging system as #10 of 14 products and services to help dentists rebound from COVID-19.
第二季,美洲地區以數位掃描儀提交的 Invisalign 總病例占比提升至 86%,高於去年第二季的 77%。國際市場的掃描占比提升至 72%,高於去年同季的 61%。我們也很高興看到在美洲地區中,北美矯正醫師提交的病例有 96% 是以數位方式提交。我們近期亦宣布 iTero Element 5D 影像系統在 2020 年 MedTech Breakthrough Awards 中獲頒「牙科最佳新技術解決方案」。該年度計畫表揚傑出的健康與醫療科技產品及公司。我們也獲得 DentistryIQ 的獎項,將 iTero Element 5D 影像系統評為協助牙醫從 COVID-19 復甦的 14 項產品與服務中的第 10 名。
With that, I'll turn the call over to John.
接下來,我把電話交給 John。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Thanks, Joe. Now for our Q2 financial results. Total revenue for the second quarter was $352.3 million, down 36.1% from the prior quarter and down 41.3% from the corresponding quarter a year ago. For clear aligners, Q2 revenues of $298.3 million was down 38.1% sequentially and down 39.9% year-over-year due to volume decreases across most regions driven by North America, EMEA and LATAM, partially offset by APAC. Clear aligner revenue growth was impacted unfavorably from foreign exchange of approximately $6 million or approximately 1 point year-over-year.
謝謝,Joe。接著說明我們第二季的財務結果。第二季總營收為 3.523 億美元,較前一季下滑 36.1%,較去年同期下滑 41.3%。就隱形矯正器而言,第二季營收為 2.983 億美元,較前一季下滑 38.1%,較去年同期下滑 39.9%,主因為多數地區出貨量下降,其中以北美、EMEA 與拉丁美洲(LATAM)帶動下滑,部分由亞太地區(APAC)抵銷。隱形矯正器營收成長亦受到外匯不利影響,年對年約 600 萬美元,約相當於 1 個百分點。
Q2 Invisalign ASPs were flat sequentially at $1,255 primarily due to promotional discounts and unfavorable foreign exchange, mostly offset by increased revenue from countries with higher list prices and increased other case revenues. On a year-over-year basis, Q2 Invisalign ASPs increased approximately $25 primarily reflecting price increases in all regions and additional aligner revenue, partially offset by promotional discounts and unfavorable foreign exchange.
第二季 Invisalign 平均售價(ASP)較前一季持平,為 1,255 美元,主要因促銷折扣與不利外匯所致,但多數被來自定價較高國家的營收增加以及其他病例營收增加所抵銷。以年對年來看,第二季 Invisalign ASP 約增加 25 美元,主要反映各地區的價格調整與額外矯正器營收,部分被促銷折扣與不利外匯所抵銷。
One example of a crisis recovery program that we implemented in Q2 was a Switch Program that enabled doctors to switch wires-and-brackets patients into Invisalign clear aligners. Total Q2 Invisalign shipments of 221,900 cases were down 38.3% sequentially and down 41.2% year-over-year. Our Systems and Services revenues for the second quarter was $54 million, down 22.2% sequentially and down 48.1% year-over-year due to volume decreases across most regions, except APAC, promotional discounts and decrease in service revenue, partially offset by exocad revenue.
我們在第二季實施的一項危機復甦方案例子,是「Switch Program」,讓醫師能將傳統鋼絲與矯正器(wires-and-brackets)患者轉換為 Invisalign 隱形矯正器。第二季 Invisalign 總出貨量為 221,900 例,較前一季下滑 38.3%,較去年同期下滑 41.2%。第二季系統與服務營收為 5,400 萬美元,較前一季下滑 22.2%,較去年同期下滑 48.1%,主因為除亞太地區(APAC)外多數地區出貨量下降、促銷折扣以及服務營收下滑,部分由 exocad 營收抵銷。
Moving on to gross margin. Second quarter overall gross margin was 63.7%, down 7.9 points sequentially and down 8.3 points year-over-year. On a non-GAAP basis, excluding stock-based compensation expense and amortization of intangibles related to exocad, overall gross margin was 64.4% for the second quarter, down 7.4 points sequentially and down 7.8 points year-over-year. Q2 gross margin reflects Align's decision to maintain our headcount and salaries across our operations in anticipation of a volume pickup as the COVID-19 pandemic subsides. This decision also enabled us to manufacture nasal test swabs for hospitals and PPE for use by our own employees as well as our doctors as they reopen their practices.
接著談毛利率。第二季整體毛利率為 63.7%,較前一季下降 7.9 個百分點,較去年同期下降 8.3 個百分點。以非 GAAP 基礎計算(排除股份基礎給付費用以及與 exocad 相關的無形資產攤銷),第二季整體毛利率為 64.4%,較前一季下降 7.4 個百分點,較去年同期下降 7.8 個百分點。第二季毛利率反映 Align 的決策:在預期 COVID-19 疫情趨緩後出貨量回升的情況下,我們維持各營運據點的人力編制與薪資。此決策也使我們得以為醫院製造鼻腔採檢拭子,並製作個人防護裝備(PPE)供自家員工及醫師在診所重新開業時使用。
We also postponed iTero subscription fees for 1 month in the U.S. and parts of APAC. On a year-over-year basis, Q2 gross margin includes approximately 0.7% impact from unfavorable foreign exchange.
我們也在美國及亞太地區(APAC)的部分市場將 iTero 訂閱費用延後 1 個月收取。以年對年來看,第二季毛利率包含約 0.7% 的不利外匯影響。
Clear aligner gross margin for the second quarter was 64.5%, down 8.5 points sequentially and down 9.2 points year-over-year due to lower volumes driving higher cost per case and increased freight costs from higher international shipment mix. On a year-over-year basis, the decrease in the clear aligner gross margin was partially offset by an increase in Invisalign ASPs and continued efficiency improvements. Systems and Services gross margin for the second quarter was 59.2%, down 2.6 points sequentially and 4.4 points year-over-year due to lower ASPs and lower volumes, with higher cost per unit and amortization of intangible assets related to the exocad acquisition, partially offset by lower service support costs.
第二季隱形矯正器毛利率為 64.5%,較前一季下降 8.5 個百分點,較去年同期下降 9.2 個百分點,主因為出貨量下降導致單案成本上升,以及國際出貨占比提高帶來的運費成本增加。以年對年來看,隱形矯正器毛利率下滑部分被 Invisalign ASP 提升與持續的效率改善所抵銷。第二季系統與服務毛利率為 59.2%,較前一季下降 2.6 個百分點,較去年同期下降 4.4 個百分點,主因為 ASP 較低與出貨量較低導致單位成本較高,以及與收購 exocad 相關的無形資產攤銷,部分由較低的服務支援成本所抵銷。
Q2 operating expenses were $297.3 million, down sequentially 8.4% and up 16.2% year-over-year. The sequential decrease in operating expenses reflects lower travel spend, decreased compensation related to commissions and lower marketing and media spend, partially offset by higher exocad acquisition costs. Year-over-year, operating expenses increased by $41.5 million. This is mainly caused by the $51 million favorable litigation settlement received in Q2 2019, offset by cost control measures in Q2 of 2020. On a non-GAAP basis, operating expenses were $265.6 million, down sequentially 11.9% and down 7% year-over-year due to the reasons as described above, offset by exocad costs.
第二季營業費用為 2.973 億美元,較前一季下降 8.4%,較去年同期增加 16.2%。營業費用的季對季下降反映差旅支出降低、與佣金相關的薪酬下降,以及行銷與媒體支出降低,部分被較高的 exocad 收購相關成本所抵銷。年對年而言,營業費用增加 4,150 萬美元,主要因 2019 年第二季收到 5,100 萬美元的有利訴訟和解款項,並由 2020 年第二季的成本控管措施部分抵銷。以非 GAAP 基礎計算,營業費用為 2.656 億美元,較前一季下降 11.9%,較去年同期下降 7%,原因如上所述,並由 exocad 成本所抵銷。
Our second quarter operating loss was $73 million, down 204.4% sequentially and down 141.4% year-over-year. Our second quarter operating margin was negative 20.7%, down 33.4 points sequentially and down 50.1 points year-over-year. The sequential decrease in operating income and operating margin are primarily attributed to lower revenues and gross margin as a result of lower volume from COVID-19 impacts. Operating margin was unfavorably impacted by approximately 0.9 points year-over-year from foreign exchange. On a year-over-year basis, the decrease in operating income and operating margin primarily reflects lower gross profit on lower volumes from the impact of COVID-19, in addition to the prior year quarter, included the $51 million favorable litigation settlement. On a non-GAAP basis, which excludes stock-based compensation, acquisition-related costs and amortization of intangibles related to exocad, operating margin for the second quarter was minus 11%, down 28.1 points sequentially and down 35.6 points year-over-year.
第二季營業損失為 7,300 萬美元,較前一季下降 204.4%,較去年同期下降 141.4%。第二季營業利益率為負 20.7%,較前一季下降 33.4 個百分點,較去年同期下降 50.1 個百分點。營業利益與營業利益率的季對季下滑主要歸因於 COVID-19 影響導致出貨量降低,進而造成營收與毛利率下降。年對年而言,營業利益率亦受到外匯不利影響約 0.9 個百分點。以年對年來看,營業利益與營業利益率下滑主要反映 COVID-19 影響下出貨量降低導致毛利減少,此外去年同期亦包含 5,100 萬美元的有利訴訟和解款項。以非 GAAP 基礎計算(排除股份基礎給付、收購相關成本以及與 exocad 相關的無形資產攤銷),第二季營業利益率為負 11%,較前一季下降 28.1 個百分點,較去年同期下降 35.6 個百分點。
Interest and other income and expense net for the quarter was an expense of $0.5 million, including a $1 million hedge loss related to the exocad acquisition. Excluding the hedge loss, interest and other income and expense net was $0.5 million income on a non-GAAP basis.
本季利息及其他損益淨額為費用 50 萬美元,其中包含與收購 exocad 相關的 100 萬美元避險損失。排除該避險損失後,以非 GAAP 基礎計算,利息及其他損益淨額為收益 50 萬美元。
With regards to the second quarter tax provision, our GAAP tax rate was 44.8%, which includes a tax benefit related to the impact of changes in the jurisdictional mix of forecasted income to GAAP profits recorded last quarter. The second quarter tax rate on a non-GAAP basis was 27.8% compared to 33.2% in prior quarter and 25.3% in the same quarter a year ago. The second quarter non-GAAP tax rate was lower than the first quarter's rate primarily due to changes in jurisdictional mix of forecasted full year results.
關於第二季所得稅費用,我們的 GAAP 有效稅率為 44.8%,其中包含一項稅務利益,係與預測所得的司法轄區組合變動對上季所認列 GAAP 利潤之影響相關。第二季非 GAAP 有效稅率為 27.8%,相較前一季為 33.2%,去年同季為 25.3%。第二季非 GAAP 稅率低於第一季,主要因預測全年結果的司法轄區組合變動所致。
Second quarter net loss per diluted share was negative $0.52, down $19.73 sequentially and down $2.35 compared to prior year. On a non-GAAP basis, net loss per diluted share was negative $0.35 for the second quarter, down $1.08 sequentially and down $1.84 year-over-year.
第二季稀釋後每股淨損為負 0.52 美元,較前一季下降 19.73 美元,較去年同期下降 2.35 美元。以非 GAAP 基礎計算,第二季稀釋後每股淨損為負 0.35 美元,較前一季下降 1.08 美元,較去年同期下降 1.84 美元。
Moving on to the balance sheet. As of June 30, 2020, cash and cash equivalents were $404.4 million, a decrease of approximately $386.3 million from the prior quarter, which is primarily due to the acquisition of exocad, partially offset by our free cash flow improvement. Of our $404.4 million of cash and cash equivalents, $160.2 million was held in the U.S. and $244.2 million was held by our international entities.
接著看資產負債表。截至 2020 年 6 月 30 日,現金及約當現金為 4.044 億美元,較前一季減少約 3.863 億美元,主要因收購 exocad,部分由自由現金流改善所抵銷。在 4.044 億美元的現金及約當現金中,1.602 億美元持有於美國,2.442 億美元由我們的海外實體持有。
Q2 accounts receivable balance was $473.3 million, down approximately 11.2% sequentially. Our overall day sales outstanding or DSOs was 121 days, up 34 days sequentially and up 44 days as compared to Q2 of last year due to doctor office closures that resulted in slower accounts receivable collections. We expect DSOs to remain relatively high as doctors' offices return -- resume normal business activity.
第二季應收帳款餘額為4.733億美元,較前一季約下降11.2%。我們整體應收帳款週轉天數(DSO)為121天,較前一季增加34天,較去年第二季增加44天,原因是醫師診所關閉導致應收帳款回收變慢。我們預期在醫師診所恢復——恢復正常營運活動之際,DSO仍將維持相對偏高。
Cash flow from operations for the second quarter was $59.9 million. Capital expenditures for the second quarter were $34.4 million primarily related to our continued investment in increasing the aligner capacity and facilities.
第二季營運活動現金流為5,990萬美元。第二季資本支出為3,440萬美元,主要與我們持續投資以提升隱形牙套產能與相關設施有關。
Free cash flow, defined as cash flow from operations less capital expenditures, amounted to $25.5 million. Under our May 2018 repurchase program, we have $100 million still available for repurchase of our common stock.
自由現金流(定義為營運活動現金流扣除資本支出)為2,550萬美元。依據我們2018年5月的庫藏股回購計畫,目前仍有1億美元可用於回購本公司普通股。
Now let me turn to our outlook. Since the last time we talked, the orthodontic and dental market has continued to evolve in response to government regulations and safety guidance of local, regional and national health officials. We believe that all of our markets have bottomed out and are recovering, albeit at different rates and different times, corresponding with regional outbreaks and recoveries from COVID-19 preventative measures as we are now seeing improvements in consumer and doctor activity. Nevertheless, we are mindful that the demand environment remains uncertain. There may be additional waves of infection, and governments around the world may strategically choose to shut down cities, states and countries again, forcing people to shelter-in-place and practices to close again. Therefore, we are not providing any forward-looking guidance.
接下來談談我們的展望。自上次與各位交流以來,矯正與牙科市場持續因應政府法規以及地方、區域與國家衛生官員的安全指引而演變。我們相信所有市場都已觸底並正在復甦,但復甦速度與時間點各不相同,取決於各地COVID-19預防措施下的區域性疫情爆發與復原情況;目前我們也看到消費者與醫師活動有所改善。儘管如此,我們仍注意到需求環境依然不確定。感染可能出現額外波次,全球各國政府也可能策略性地再次關閉城市、州或國家,迫使民眾居家避難並使診所再度關閉。因此,我們不提供任何前瞻性指引。
While our management team understands the markets remain fluid, we continue to focus on taking care of our employees, customers and shareholders. Specifically, for our employees, we are committed to protecting our employees and do not intend to implement furloughs or salary reductions. For our customers, we will continue to be supportive of our customers who are impacted by COVID-19 and are committed to helping slow the spread of the virus by providing PPE to doctors. We continue to release products, tools and promotions to help our doctors recover from the crisis. For our shareholders, we will continue to invest in our strategic initiatives to grow in a vastly underpenetrated market and position our company to capture growth as the market returns to normal. This includes continued investment in Align's end-to-end digital workflow as well as increased investment in the Invisalign brand and consumer demand creation, as you heard Joe describe earlier. We will continue to add resources in markets that give us a good return.
雖然管理團隊理解市場仍在變動,我們仍持續專注於照顧員工、客戶與股東。具體而言,對員工方面,我們致力於保護員工,並無意實施無薪假或減薪。對客戶方面,我們將持續支持受COVID-19影響的客戶,並承諾透過向醫師提供個人防護裝備(PPE)來協助減緩病毒傳播。我們也持續推出產品、工具與促銷活動,協助醫師從危機中復原。對股東方面,我們將持續投資於策略性計畫,在滲透率仍然偏低的市場中成長,並在市場回歸正常時讓公司具備掌握成長的定位。這包括持續投資Align端到端的數位工作流程,以及加大對Invisalign品牌與消費者需求創造的投資,正如先前Joe所描述。我們也將持續在能帶來良好報酬的市場增加資源投入。
I'm very proud of what Align has accomplished while maintaining our financial discipline during this pandemic. We finished Q2 with $404.4 million in cash and cash equivalents, closed the purchase of exocad for $430 million and still delivered free cash flow of $25.5 million despite having the lowest volume Align has had in a very long time. Our cash flow reflects the strength of our business model, the strength of our balance sheet and our strong operational focus.
我對Align在這場疫情期間仍能維持財務紀律並取得的成果感到非常自豪。我們在第二季結束時持有4.044億美元的現金及約當現金,完成以4.30億美元收購exocad,且儘管Align的出貨量處於很長一段時間以來的最低水準,仍交出2,550萬美元的自由現金流。我們的現金流反映了商業模式的韌性、資產負債表的強健,以及我們對營運的高度聚焦。
I'm also pleased to share that we have established a new line of credit of $300 million with a consortium of banks led by Citibank. This new line replaces our line of credit with Wells Fargo. As the market leader in clear aligners and digital dentistry, we are well positioned to continue investing strategically for the future.
我也很高興分享,我們已與由花旗銀行(Citibank)領軍的銀行團建立一條新的3億美元信用額度。這條新額度取代了我們與富國銀行(Wells Fargo)的信用額度。作為透明牙套與數位牙科的市場領導者,我們具備良好條件,得以持續為未來進行策略性投資。
With that, I'll turn it back to Joe for final comments. Joe?
接下來我把時間交還給Joe做最後的評論。Joe?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Thanks, John. In summary, we're pleased with our progress last quarter and by the customer responses to the actions we've been taking to support their practices and patients. We have developed a careful recovery approach that accounts for the safety of our employees, our customers and their teams and their patients and are committed to helping doctors navigate this evolving environment and be successful.
謝謝你,John。總結來說,我們對上季的進展以及客戶對我們為支持其診所與病患所採取行動的回饋感到滿意。我們制定了審慎的復甦方法,兼顧員工、客戶及其團隊與病患的安全,並承諾協助醫師在這個不斷演變的環境中前行並取得成功。
One of the biggest lessons we have learned over the last few months is about the critical importance of digital technology. Align has always been a proponent of digital treatment. But think about all the things that digital platforms and virtual tools have enabled during the crisis: the people in the businesses and the customers who stayed connected, the way we were able to adapt to working from home, the rise of telehealth and teleconsults, the AI that modeled the virus patterns and informed health experts and so much more. Consider also the companies that have thrived, most are companies that are digital at their core, Amazon, apple, Zoom, DocuSign, Netflix, InstaCart, just to name a few.
過去幾個月我們學到的最大教訓之一,是數位科技的關鍵重要性。Align一向支持數位化治療。但想想在危機期間,數位平台與虛擬工具促成了多少事情:企業內部的人員與客戶得以保持連結、我們能夠適應居家工作、遠距醫療與遠距諮詢的興起、用於建模病毒傳播模式並為衛生專家提供資訊的AI,還有更多。此外也看看那些蓬勃發展的公司,多數都是以數位為核心的公司,例如Amazon、Apple、Zoom、DocuSign、Netflix、InstaCart等,僅舉幾例。
The advantage of digital are much more magnified to practitioners and consumers. This became even clearer in our industry when practices were shut down for months. Over and over, we heard, "I've been able to help my Invisalign patients progress in treatment, but I had to just try to keep my patients in a holding pattern with wires and brackets." Treating orthodontic cases has amplified the clear benefits of digital technology in clear aligners. This isn't meant to sound self-serving. This pandemic has emphasized the benefits of digital technology across many facets of our lives and businesses. Our acquisition of exocad adds additional digital workflows that play in the GP space and lab space. We're all excited about the exocad team and what our investment brings to this new world of digital dentistry.
數位化的優勢對臨床醫師與消費者而言更為放大。當診所一關就是數個月時,這在我們產業變得更加明顯。我們一再聽到:「我能夠幫助我的Invisalign病患持續推進治療,但對於使用鋼絲與矯正器的病患,我只能盡量讓他們維持在原地不動的狀態。」在矯正病例的治療上,透明牙套更凸顯了數位科技的明確效益。這並非自我吹捧;這場疫情強調了數位科技在我們生活與企業多個面向的好處。我們收購exocad,新增了可應用於一般牙科(GP)與技工所(lab)領域的更多數位工作流程。我們都對exocad團隊以及我們的投資能為這個數位牙科新世界帶來的價值感到興奮。
Align's digital platform has made it possible for thousands of doctors and patients to continue Invisalign treatment throughout a global disruption, thanks to the digital orthodontics of Invisalign aligners, iTero digital records and simulations, digital treatment planning and virtual monitoring and care. At Align, we've always believed that digital orthodontics is the best option for teens and adults. As you can see from a peek at our new teen campaign, we're going to feature this going forward. What's clear to us is that the momentum we're seeing in the business and in the dental and ortho practices reflects more than just one thing or one new product or tool or one program or action. It reflects continuous improvement and continued execution of our core strategy across our business in every region. We're going to continue to stay the course while remaining vigilant and agile.
Align的數位平台使數以千計的醫師與病患得以在全球性中斷期間持續進行Invisalign治療,這要歸功於Invisalign隱形牙套的數位矯正、iTero數位紀錄與模擬、數位治療規劃,以及虛擬監測與照護。在Align,我們一直相信數位矯正是青少年與成人的最佳選擇。從我們全新的青少年行銷活動一瞥即可看出,我們未來將持續主打這一點。我們清楚看到,業務與牙科及矯正診所的動能並非僅由單一因素、單一新產品或工具、單一方案或行動所驅動;而是反映我們在各地區、整個業務中對核心策略的持續改善與持續執行。我們將在保持警覺與敏捷的同時,持續堅持既定方向。
We feel good about the progress that we have made. And as we continue along the recovery phase of COVID-19 crisis in many regions, we are focused on what we can control and impact. We are in a unique position to continue investing into a huge underpenetrated market to extend our lead and accelerate growth.
我們對已取得的進展感到樂觀。隨著許多地區持續進入COVID-19危機的復甦階段,我們專注於我們能控制並能產生影響的事項。我們處於獨特位置,得以持續投資於一個滲透率仍很低的龐大市場,擴大領先並加速成長。
With that, I want to thank you again for joining our call. I look forward to updating you on our progress as the year unfolds.
最後,再次感謝各位參與本次電話會議。我期待在今年接下來的進程中,持續向各位更新我們的進展。
Now I'll turn the call over to the operator for questions. Operator?
現在我把電話交給接線員進行問答。接線員?
Operator
Operator
(Operator Instructions) Our first question comes from the line of Nathan Rich with Goldman Sachs.
(接線員指示)我們的第一個問題來自高盛(Goldman Sachs)的Nathan Rich。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Joe, you highlighted the improvement in utilization that you saw in June. I understand sort of the rationale for not providing guidance for 3Q, kind of given the situation. But can you maybe help us better understand kind of where the business stood kind of at the end of June, just so we have a better sense of sort of what the jumping-off point is as we think about the back half of the year?
Joe,你提到你在6月看到的使用率改善。我理解在目前情況下不提供第三季指引的理由。不過你能否協助我們更好地理解,6月底時業務大致處於什麼狀態,讓我們在思考下半年時更清楚起跳點大概在哪裡?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I mean we saw dramatic improvement between April and June. Obviously, we were kind of in the jaws of COVID-19 with all the shutdowns and all in April. May was a little better, and then we were seeing strong momentum as we've moved into June. So I think you can look at that as a significant improvement in our business overall.
是的。我們在4月到6月之間看到顯著改善。很明顯,4月在各種封鎖之下,我們幾乎正處於COVID-19的風暴中心。5月稍微好一些,而進入6月後我們看到強勁動能。因此我認為,你可以把這視為我們整體業務的重大改善。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Okay. Great. And then you highlighted the 3,000 customers that were new to Invisalign this quarter. Can you maybe just talk about how that compares to maybe what you see in a typical quarter and kind of what you're doing to ensure that those doctors become kind of longer-term customers of Invisalign?
好的。謝謝。接著你提到本季有3,000位首次使用Invisalign的新客戶。你能否談談這與一般季度相比如何,以及你們做了哪些事情來確保這些醫師能成為Invisalign較長期的客戶?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I mean that's -- I mean when you think about COVID-19 and what the business has really faced in that, 3,000 customers to us was terrific in that way, right? I mean you don't actually look for new customers coming in on that. You're looking for utilization rates on your current base. So I mean we felt -- and I felt really great about the 3,000, and obviously, that got stronger as the quarter went on.
是的。我的意思是——當你想到COVID-19以及業務所面臨的情況時,對我們而言3,000位客戶在那樣的情境下非常出色,對吧?因為在那種情況下,你其實不太會期待有新客戶加入;你更關注的是現有客戶基礎的使用率。所以我們覺得——我也對這3,000位感到非常振奮,而且很明顯,隨著季度推進,情況也變得更強勁。
Operator
Operator
Our next question comes from the line of Elizabeth Anderson with Evercore.
下一個問題來自 Evercore 的 Elizabeth Anderson。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Can you talk about -- do you think Asia is a good path to think about in terms of the recovery? Or do you see sort of significant differences in that geography that would -- that should prevent us from extrapolating?
你能談談——你認為從復甦的角度來看,亞洲是一條好的路徑嗎?還是你看到該地理區域存在某些顯著差異——會——使我們不應該直接外推?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I think it's -- Asia is so diverse in itself. It's hard just to extrapolate Asia, Elizabeth. I mean obviously, China was kind of first out of this thing. But China has had a bumpy road also with the recent issues in Shanghai and different areas. So every one of these regions has its own unique footprint and its own unique model in the sense of how they've dealt with the virus. But I don't -- obviously, it's in our transcript here, but we see significant improvement in really every region around the world.
是的。我認為——亞洲本身就非常多元。很難就這樣外推整個亞洲,Elizabeth。我的意思是,顯然中國算是最早走出這件事的。但中國最近在上海及其他地區的問題上也走得顛簸。所以這些地區各自都有其獨特的樣貌,以及在如何應對病毒方面各自獨特的模式。但我不——顯然這也在我們的逐字稿裡,不過我們看到全球幾乎每個地區都有顯著改善。
Elizabeth Hammell Anderson - Associate
Elizabeth Hammell Anderson - Associate
Okay. And I think you commented also in terms of your cost structure, in terms of not furloughing or laying off employees. Is there any other major changes to the cost structure in like the third quarter, maybe just in the back half of the year generally, that we should think about as we're updating our models?
好的。另外我想你也提到你們的成本結構,像是不讓員工停薪留職或裁員。那在第三季,或更一般地說在今年下半年,成本結構還有其他重大變化是我們在更新模型時應該考量的嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Hi, Elizabeth. This is John. No, we continue to believe in our model. It's a vastly underpenetrated market. We're going to make strategic investments to be able to grow in that market. Whether it's R&D, sales, marketing, we're going to continue to make those investments where we see a return.
嗨,Elizabeth。我是 John。沒有,我們仍然相信我們的模式。這是一個滲透率仍然非常低的市場。我們會進行策略性投資,以便在該市場成長。不論是研發、銷售、行銷,只要我們看到有回報,就會持續投入這些投資。
Operator
Operator
Our next question comes from the line of Steve Beuchaw with Wolfe Research.
下一個問題來自 Wolfe Research 的 Steve Beuchaw。
Stephen Christopher Beuchaw - Director of Equity Research
Stephen Christopher Beuchaw - Director of Equity Research
I wonder, first, Joe, could you give us any more color on the breadth of uptake of some of the new digital tools that you referred to and the extent to which practices are making these changes and converting over to something of a "virtual” experience. I mean is this 2% of your customer base? Or is it a lot bigger than that? Any color is really, really helpful there.
我想先問,Joe,你能否就你提到的一些新數位工具的採用廣度,以及診所實務在多大程度上正在做這些改變、轉向某種「虛擬」體驗,提供更多細節?我的意思是,這是你們客戶群的 2% 嗎?還是遠大於此?任何補充都會非常、非常有幫助。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Steve, when we talk about a digital platform, you really start with iTero on the front end, right? Even in a downturn like we saw with COVID, in the capital equipment business, iTero was -- showed up well and then particularly with 5D in different areas. But that's the front end of this whole piece that we talk about on a digital platform. Then you move through our, obviously, our treatment planning and all. But what we added, when you think about the whole breadth of a global digital platform, we added virtual care that you knew about, and we came out so that doctors could talk to their patients remotely and be able to track treatment. And actually, we had several doctors actually close cases remotely with our virtual treatment capability. And that really extended the effectiveness of the doctors and the effectiveness of the digital treatment in that sense, too.
Steve,當我們談到數位平台時,你其實是從前端的 iTero 開始,對吧?即使在像 COVID 期間我們看到的那種下行環境中,在資本設備業務裡,iTero——表現得很不錯,尤其是 5D 在不同領域的應用。但那只是我們所說的數位平台這整個環節的前端。接著你會進入我們的——顯然——治療規劃等等。但當你思考全球數位平台的整體廣度時,我們新增了你已經知道的虛擬照護,我們推出讓醫師可以遠端與病患溝通並追蹤治療的功能。事實上,我們有好幾位醫師透過我們的虛擬治療能力在遠端完成結案。這也在某種意義上延伸了醫師的效能,以及數位治療的效能。
There's a lot of imaging that we do now in our treatment planning, in all too, and so it's not just tracking patients. It's also having images and different things that you can share with patients in the sense of where they should be around treatment in those types of areas. So it's a broad kind of a digital platform we're talking about. I mean we had tens of thousands of people on our virtual care platform as we roll that thing out in a matter of 30 days and then all around the world. And we'll continue to update that platform with AI. We'll make it much more predictive so that doctors don't have to look at every patient. We have a strong road map in that sense too, Steve. So it's just -- it's the breadth of a digital platform and how it covers everything, from starting with a consumer, turning them into a patient, from iTero all the way to the back end and being able to monitor and treat those patients.
我們現在在治療規劃等方面也做了大量影像處理,所以不只是追蹤病患而已。也包括影像以及你可以與病患分享的各種內容,讓他們了解在治療進程中應該處於什麼狀態、以及相關領域的資訊。所以我們談的是一個相當廣泛的數位平台。我的意思是,我們在 30 天內推出虛擬照護平台,並在全球推廣,平台上就有數以萬計的人。我們也會持續用 AI 更新該平台,讓它更具預測性,如此醫師就不必查看每一位病患。我們在這方面也有很強的路線圖,Steve。所以這就是——數位平台的廣度,以及它如何涵蓋所有環節:從接觸消費者、把他們轉化為病患,從 iTero 一直到後端,並能夠監測與治療這些病患。
Stephen Christopher Beuchaw - Director of Equity Research
Stephen Christopher Beuchaw - Director of Equity Research
Got it. And just one more for me. What I'm trying to get to here is some perspective on what the underlying trend is. And I appreciate that you don't want to talk about the exit rate leaving 2Q and you're not going to give guidance for 3Q. But what if I said, let's imagine a scenario where we don't have another wave of lockdowns, where practices are operating in what is admittedly a challenging environment, but we don't have any sort of government level or professional society level edict that says, "Hey, you got to stop doing cases or stop engaging in practices." If that's the operating environment we're in, I mean, can you grow in 3Q or the back half of the year? Can you speak at all to what the business would like -- look like in that situation if we don't get more lockdowns?
了解。再問最後一個。我想要得到的是對基本趨勢的一些觀點。我也理解你們不想談第二季結束時的退出率,而且你們也不會給第三季指引。但如果我這樣說:假設我們不會再出現另一波封鎖,診所是在一個確實具挑戰的環境中運作,但沒有任何政府層級或專業學會層級的命令說「嘿,你必須停止做病例或停止執業」。如果我們所處的營運環境是這樣,我的意思是,你們在第三季或今年下半年能成長嗎?如果不再有更多封鎖,你能否談談在那種情況下業務會——看起來如何?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Hey, Steve, I'd say we're incredibly optimistic in the scenario that you painted, where we don't see another COVID shutdown in a major market that lasts a long period of time. Based on the recoveries that we've seen in the latter half of May and then the strong recovery in June, we feel really good about the future of this business in the third and fourth quarter and beyond. John, anything to add?
嘿,Steve,我會說在你描繪的情境下,我們非常樂觀,也就是我們不會在某個主要市場看到另一個持續很長時間的 COVID 停擺。基於我們在 5 月下旬看到的復甦,以及 6 月強勁的復甦,我們對第三季、第四季以及更長遠的業務前景感到非常有信心。John,有什麼要補充的嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, that covers it.
是的,這樣就涵蓋了。
Operator
Operator
Our next question comes from the line of Jon Block with Stifel.
下一個問題來自 Stifel 的 Jon Block。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Hey, Joe, hopefully you can hear me okay.
嘿,Joe,希望你聽得到我。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes, we do.
是的,我們聽得到。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
I want -- in somewhat of a similar line of questioning, just sort of inundated with e-mails about sort of trends, so let me try to frame it this way. I think it was Slide 8. You guys said increase in North American utilization for June. I think first part of the question, I just want to be clear, that was for both orthos and GPs? I thought the slide was hard to tease that out.
我想——問題方向有點類似,只是我收到很多關於趨勢的電子郵件,所以我試著這樣表述。我想是第 8 張投影片。你們說 6 月北美使用率增加。我想第一部分我只是想確認,那是同時包含矯正專科(ortho)和一般牙科(GP)嗎?我覺得那張投影片不太容易看出來。
And then if that's the case, Joe, was that pure? In other words, I'm getting questions on practices reopened in May. And obviously, there's a lot of backlog. So you're saying North America grew in June. But was it pure? Was it a benefit of backlog? And maybe if you can comment if that growth continued into July would be very helpful for North America.
然後如果是這樣,Joe,那是「純粹」的成長嗎?換句話說,我收到的問題是診所在 5 月重新開業,而顯然有很多積壓需求。所以你說北美在 6 月成長。但那是純粹成長嗎?還是受惠於積壓需求?另外,如果你能評論這個成長是否延續到 7 月,對北美會非常有幫助。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Hey, Jon. This is John. Some of that is -- some of it's backlog and some of it's additional growth that they would have. So the utilization has improved as those doctors have come back to work and they're seeing patients. And that's true in North America, and that's true in all countries where we see those doctors' offices opening up. So it's hard to tell how much is backlog versus how much is more run rate going forward, but we're seeing a combination of them both.
嘿,Jon。我是 John。其中一部分是——一部分是積壓需求,另一部分是他們本來就會有的額外成長。所以隨著那些醫師回到工作崗位並開始看診,使用率就改善了。這在北美如此,在所有我們看到診所重新開門的國家也都是如此。所以很難判斷有多少是積壓需求、多少是未來更常態化的運行水準(run rate),但我們看到兩者的組合。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
And the second part of that question, John, while I've got you, that increase, or the year-over-year growth in North America, does that continue into the month of July?
那個問題的第二部分,John,趁你在——北美的那個增加、也就是北美的年增成長,是否延續到 7 月?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We have got momentum and continue to be strong, Jon.
我們有動能,而且持續強勁,Jon。
Jonathan David Block - MD & Senior Equity Research Analyst
Jonathan David Block - MD & Senior Equity Research Analyst
Okay. Fantastic. And the second part of the question, I'll go from very near term, next month, to sort of 18 months out, 24 months out. John, just as we think about the model longer term, I think The Street has you guys, from a 2021 perspective, revenue is higher in '21 than '19. Let's throw away 2020 for a whole host of reasons. But let's look '21 versus '19. Structurally, if revs are higher by x percent, should the margin structure also be higher? I look back to '19, you had some one-timers in legal, et cetera. You reset the base ex stock-based comp. But if that were the case, I'm just trying to figure out, do you think the margin profile would also follow when we look out at the earnings power?
好的。太好了。那第二部分的問題,我會從非常短期的下個月,拉到大約 18 個月、24 個月。John,當我們從較長期來思考這個模型時,我想華爾街對你們的預期是,從 2021 年的角度看,2021 年營收高於 2019 年。基於各種原因我們先把 2020 年放一邊。但我們看 2021 對 2019。結構上,如果營收高出 x%,那麼利潤率結構也應該更高嗎?我回頭看 2019 年,你們在法律等方面有一些一次性項目。你們也在扣除股權薪酬後重設了基礎。如果是那樣,我只是想弄清楚,當我們展望獲利能力(earnings power)時,你認為利潤率輪廓也會跟著走嗎?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. Thanks, Jon. So as we look at investing, our long -- we believe in our long-term model, our long-term growth model, and that has upped margin at the 25-plus percent. So that's how we look to keep investing. As you get some benefit through the expansion and other things, you might get some leverage as you go, but we believe in that long-term model, and that's how we look forward on our investments.
是的。謝謝,Jon。所以當我們看投資時,我們的長——我們相信我們的長期模式、長期成長模式,而該模式的利潤率提升到 25% 以上。這就是我們看待持續投資的方式。當你透過規模擴張和其他因素獲得一些效益時,隨著進展你可能會得到一些營運槓桿,但我們相信那個長期模式,而這也是我們在投資上向前看的方式。
Operator
Operator
Our next question comes from the line of Ravi Misra with Berenberg Capital Markets.
下一個問題來自 Berenberg Capital Markets 的 Ravi Misra。
Ravi Misra - Analyst
Ravi Misra - Analyst
So just, first, I wanted to ask, you gave us some sort of inclination about what the COVID impact was in Q1. Anything that you can provide color-wise on that for Q2?
所以首先我想問一下,你們之前大概提到過第一季 COVID 的影響。第二季在這方面你們還能提供一些補充說明嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I think, Ravi, what we could tell you is, I mean, obviously, April was tough as we came out of March into April. We saw some stabilization in May and then good progress in June overall. So just a complete kind of beginning and end to that quarter overall. And like we just mentioned to Jon, is that that's continued into July also.
是的。我想,Ravi,我們可以告訴你的是,顯然從三月進入四月時,四月很艱難。我們在五月看到一些趨於穩定,六月整體也有不錯的進展。所以整個季度從開頭到結尾呈現出完全不同的狀態。就像我們剛剛跟 Jon 提到的,這樣的趨勢在七月也持續。
Ravi Misra - Analyst
Ravi Misra - Analyst
Okay. I guess it's going to be hard to get a dollar figure out of you guys. How about just on ADAPT, I'm curious about the business model here when you're talking about kind of increase in utilization. Can you help us think about how you plan on monetizing that? Is there some sort of profit-sharing or revenue-sharing that it comes to the increased caseload? And when does that kind of start to kind of flow through the P&L? Should we expect this as a 2021 event? Or when -- is this a small program that shouldn't really have a material impact to revenue?
了解。我猜要你們給出一個美元金額可能很難。那關於 ADAPT,我對你們提到的使用率提升下的商業模式很好奇。你們打算如何把這件事變現?是否會有某種利潤分成或營收分成,與增加的病例量相關?這大概什麼時候會開始反映在損益表上?我們應該把它視為 2021 年的事件嗎?還是——這其實是一個規模很小、對營收不會有重大影響的計畫?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Well, Ravi, this is John. So you're talking about the ADAPT program that we spoke about?
嗯,Ravi,我是 John。你是在說我們提到的 ADAPT 計畫嗎?
Ravi Misra - Analyst
Ravi Misra - Analyst
Yes. Yes.
是的。是的。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Look, we believe in the digital transformation, and this is the way we've seen it in testing that we've done to be able to help practices be more efficient, moving from analog to digital. We believe in that platform and believe in that process. And these are initiatives that we'll take to help with that. It will be a service for a fee. And those doctors, those practices, will see the benefit. We've seen it time after time on those practices that they've seen improvement in their efficiency and profitability, and we want to be able to provide that service.
你看,我們相信數位轉型,而我們在所做的測試中看到,這是能夠幫助診所提升效率、從類比走向數位的方式。我們相信這個平台,也相信這個流程。這些都是我們會推動的措施來協助轉型。它會是一項收費服務。那些醫師、那些診所會看到效益。我們一次又一次看到,那些診所的效率與獲利能力都有改善,而我們希望能提供這項服務。
Ravi Misra - Analyst
Ravi Misra - Analyst
Kind of an upfront payment?
有點像一次性的前期付款?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, I think the way we bill for that will be probably different by region. But it is -- it's not an easy transition for practitioners to go from analog to digital. And we've known that it's been one of the frictional points of customers wanting to, obviously, to go digital from a dentistry standpoint, orthodontics standpoint. So we've learned a lot, and we're using those learnings for customers that reach out and really want to make a commitment for a digital transition. And we know we can help. We piloted it last year in every region, and we roll it out full force now.
嗯,我想我們對這項服務的計費方式可能會因地區而異。但對執業者而言,從類比轉到數位並不容易。我們也知道,這一直是客戶想要——當然——從牙科、矯正的角度走向數位時的一個摩擦點。所以我們學到了很多,而我們正把這些經驗用在那些主動聯繫、並且真的想承諾進行數位轉型的客戶身上。我們知道我們能幫上忙。我們去年在各個地區都做了試點,現在正全面推廣。
Operator
Operator
Our next question comes from the line of Steven Valiquette with Barclays.
下一個問題來自 Barclays 的 Steven Valiquette。
Steven James Valiquette - Research Analyst
Steven James Valiquette - Research Analyst
So you guys mentioned the -- that braces buyback program, which has some success with 2,500 patients switches. I guess I was curious whether that program is something you expect to turn into substantially larger numbers in the remainder of 2020. Or is that going to be maybe a smaller part of the overall picture? Also, did you do that just in North America? Or are you planning to do that in most regions?
你們提到那個——牙套買回計畫,已經有一些成果,完成了 2,500 位患者的轉換。我想問的是,你們是否預期這個計畫在 2020 年剩餘時間會擴大到顯著更大的數量?還是它可能只是整體版圖中的一小部分?另外,你們只在北美做嗎?還是計畫在大多數地區推行?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We -- yes, we have been doing that program in different countries in Asia for a while. So I mean we knew how to implement it. We thought it was a good time in North America, obviously, because of some doctors being trapped with their wires-and-brackets patients and their inability to help them. So will we continue that? We'll continue it through this quarter. If we -- whether we continue it or not will be really based on what consumer needs are and what doctors' needs are. But we'll make that decision when the time comes. But we're just trying to help in the moment in the sense of doctors being able to control their practices and help their patients.
我們——是的,我們在亞洲不同國家做這個計畫已經有一段時間了。所以我們知道如何落地執行。我們認為在北美這是個好時機,因為顯然有些醫師被他們的鋼絲與托槽患者「卡住」,而且無法好好協助他們。那我們會不會繼續?我們會在本季持續推行。至於之後是否繼續,將主要取決於消費者需求以及醫師的需求。我們會在適當時點做決定。但我們現在只是想在當下提供協助,讓醫師能夠掌控他們的診所並幫助他們的患者。
Steven James Valiquette - Research Analyst
Steven James Valiquette - Research Analyst
Okay. Finally, my preteen daughter was wondering if you can say hi to Charli D' Amelio for her when you get a chance.
好的。最後,我家青春期前的女兒想問,你們有機會的話能不能替她跟 Charli D' Amelio 打個招呼。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
John and Shirley know her better than I do, but they will put a good word in for her, okay?
John 和 Shirley 比我更認識她,不過他們會幫她美言幾句的,好嗎?
Operator
Operator
Our next question comes from the line of Matthew O'Brien with Piper Sandler.
下一個問題來自 Piper Sandler 的 Matthew O'Brien。
Matthew Oliver O'Brien - MD & Senior Research Analyst
Matthew Oliver O'Brien - MD & Senior Research Analyst
Just for starters, just as we think about the recovery here in Q2, and I look at the adult number on a worldwide basis, looks like it was down 45, teen was down 32, per my math. But obviously, in the U.S. or North America, that number was much lower. So with the higher unemployment rate, with more people kind of staying at home, how does the adult market in the U.S. recover during the back half of the year?
先從基本面開始,當我們看第二季的復甦情況,我看全球口徑的成人數據,按我的計算大概下滑 45%,青少年下滑 32%。但很明顯在美國或北美,這個數字要低得多。那在失業率較高、更多人待在家裡的情況下,美國成人市場在下半年會如何復甦?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, I think it's honestly hard to call that. I mean obviously, what you're pointing out, are teens are -- and this is the seasonal time for teens, and we know we'll get a strong signal here in the third quarter. But we're optimistic about adults. I think there's a lot of -- just talking to different people in the marketplace, and you know this too, there seems to be a lot of people with time on their hands, wanting to do elective procedures that they haven't had time to do before. And we're picking this up all around the country. So unlike 2008, where a lot of things kind of folded up because people were worried about their personal wealth, even though people are sheltering in place or socially distancing, and especially our demographic that we work through right now, seems to have more time on their hands too to be able to pursue these kinds of things. So we're relatively optimistic on the adult segment going forward, third, fourth quarter also.
嗯,我覺得老實說這很難判斷。你指出的很對,青少年——而且這是青少年的季節性旺季,我們也知道第三季會看到很強的訊號。但我們對成人市場是樂觀的。我想市場上——跟不同的人聊,你也知道——似乎有很多人手上有時間,想做一些以前沒時間做的選擇性療程。我們在全國各地都觀察到這點。所以不像 2008 年,很多事情因為人們擔心個人財富而停擺;即使大家居家避疫或保持社交距離,尤其是我們目前服務的客群,似乎也有更多時間去追求這類事情。因此我們對成人族群未來第三、第四季也相對樂觀。
Matthew Oliver O'Brien - MD & Senior Research Analyst
Matthew Oliver O'Brien - MD & Senior Research Analyst
Okay. And then the follow-up question, Joe, just to your point about all this enthusiasm that you're seeing going forward, and you're holding SG&A higher, gross margins are taking a hit right now because you're keeping folks in place. You've got all this optimism. The doc training number was down a little bit, but obviously, that's COVID-related. So can you just kind of illuminate a little bit more where all this enthusiasm and optimism comes from as we start thinking beyond this year? Were your touch points on the doc side in terms of virtual, plus in-person, way higher? I guess what everybody is trying to get their hands on, because of COVID, do you think this could accelerate the adoption of clear aligners versus traditional brackets and wires, given all the benefits of less office visits, et cetera?
好的。那追問一下,Joe,延續你提到的你們對未來看到的這些熱度,你們把 SG&A 維持在較高水準,因為你們把人員留在原位,毛利率目前也受到衝擊。你們又這麼樂觀。醫師培訓的數量有小幅下降,但顯然是 COVID 相關。你能不能再多說一點,當我們開始思考今年之後,這些熱情與樂觀到底來自哪裡?你們在醫師端的觸達(虛擬加上實體)是不是高很多?我想大家都想搞清楚的是,因為 COVID,你覺得這會不會加速透明牙套相對於傳統托槽鋼絲的採用,畢竟它有更少回診等好處?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Matt, you asked the million-dollar question, right, or the billion-dollar question, all right? We think -- I mean obviously, we're -- our story has always been we're way underpenetrated in this marketplace based on what consumers want, based on what our technology can do from a clinical standpoint, the consumer experience that's going on. I think we all think that COVID has really shined a light on this, a much less invasive treatment, much easier in the sense from a patient standpoint, much better workflow for doctors to keep track of their patients.
Matt,你問到百萬美元的問題,對吧——或者十億美元的問題,好嗎?我們認為——我的意思是,顯然,我們的故事一直是:基於消費者想要的、基於我們技術在臨床端能做到的,以及正在發生的消費者體驗,這個市場的滲透率仍然非常低。我想我們都認為 COVID 真的讓這件事被看見:一種侵入性更低的治療,從患者角度更容易,對醫師而言也有更好的工作流程來追蹤患者。
So we think, if anything, this is the time that this could happen. We're not telling you that this is the tipping point on the entire thing, but we certainly say this isn't hurting our story. And it's certainly being supported out there, not just in the United States, but broadly around the world.
所以我們認為,如果有什麼時點可能發生,那就是現在。我們不是在告訴你這就是整體市場的臨界點,但我們確實會說,這並沒有傷害我們的故事。而且這在外部也獲得支持,不只是在美國,而是在全球更廣泛的範圍。
Operator
Operator
Our next question comes from the line of John Kreger with William Blair.
下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Just following up on Matt's question, just if you could give us your sense about how you view the attitude of the consumer right now, they had this sort of forced deferral as practices shut down. But now the practices are reopened, what is your sense about the willingness of the consumer to sort of step up and make this purchase? Does it feel like business is normal or still very much kind of in a wait-and-see mode?
延續 Matt 的問題,如果你能談談你們現在如何看待消費者的態度:診所關閉期間,消費者被迫延後。但現在診所重新開放,你們對消費者願意站出來做這筆購買的意願有何看法?感覺生意已經回到正常,還是仍然很大程度處於觀望模式?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, it feels like as we're in a teen season, we've talked about this before, John, that this is -- we call these elective procedures, but teens have a certain clinical window that they fit into, and it's always a time frame with parents. And we're very optimistic that, that kind of teen focus and growth will continue in the third quarter, in China too, in the United States and different places. But also, this is a different -- John, this is different than 2008, from what we feel, is consumers seem to have more optimism in the sense of the economy. You see it in the stock market right now. We all see it there. And they have more time on their hands with many people not working from offices.
嗯,感覺是,既然我們正處於青少年旺季——我們以前也談過,John——這些我們稱為選擇性療程,但青少年有一個特定的臨床時間窗必須配合,對家長而言也總是有時間壓力。我們非常樂觀,這種以青少年為重點的成長會在第三季持續,在中國也是,在美國以及其他地方也是。同時,John,這跟 2008 年不同。我們的感受是,消費者對經濟似乎更樂觀。你現在從股市就看得出來,我們都看得到。而且很多人不必到辦公室上班,手上的時間也更多。
And so we're optimistic again that there's money out there, and there's a willingness with patients to pursue these elective treatments. And I think you also have to look at the aesthetic markets from a surgical standpoint and see what's going on there, too. It seems to support that kind of an idea also. So it's a -- this is different than what we've seen in past recessions, for sure. I'm not a registered economist. Neither is John. We're good at Invisalign in this business, and that's where we can only just reiterate to you the signals we're seeing in the marketplace. But right now, as this comes back, we know that all dental offices aren't completely up to speed, but that's not necessarily based on demand. That's based on the way that they have to actually pace these patients through their practices to make sure that they keep their staff safe and they keep these patients safe, too.
因此,我們再次感到樂觀,認為市場上仍有資金,而且患者也願意去進行這些選擇性的治療。我認為你也必須從外科手術的角度去看醫美市場,看看那邊的情況如何。看起來也支持這樣的想法。所以這——這確實不同於我們在過去景氣衰退中所看到的情況。我不是註冊經濟學家,John 也不是。我們在這個業務上擅長的是 Invisalign,而我們只能再次向你重申我們在市場上看到的訊號。但目前,隨著業務回升,我們知道並非所有牙科診所都已完全恢復到正常運作,但那不一定是因為需求問題,而是因為他們必須以實際可行的節奏安排患者在診所內的流程,以確保員工安全,也確保患者安全。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Great. Great. And then one last one. You mentioned being still very much committed to innovation. Can you give us an update there, how is mandibular advancement being adopted? And any update on palate expansion?
很好,很好。最後一個問題。你提到仍然非常致力於創新。能否請你更新一下:下顎前移(mandibular advancement)的採用情況如何?另外,對於顎腭擴弓(palate expansion)有沒有任何最新進展?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. It's hard to take the second quarter on MA and give you a trend because it was a pretty hard hit overall, obviously, from -- you saw from our numbers. I'd say, overall, mandibular advancement continues to go well. We pair it with our teen first product, Invisalign First product line, which is doing extremely well also. And so what you really find around the world, John, is you find some docs that are just glued to mandibular advancement. They love it. They use it every day. Other ones are trying it out, that they've had it on some patients and they're watching through it. On the First product line, they kind of combine that together. And so we see a significant increase in what I call our clinical penetration because we can do those kinds of cases that we couldn't really have done really 2 years ago at all.
是的。要用第二季的 MA 來給你一個趨勢其實很難,因為整體受到的衝擊相當大,顯然——你從我們的數字也看得出來。我會說,整體而言,下顎前移的進展仍然不錯。我們會把它和我們的青少年早期產品——Invisalign First 產品線——搭配使用,而那條產品線的表現也非常好。因此你在全球各地真正看到的情況是,John,有些醫師就是非常依賴下顎前移,他們很喜歡,天天都在用;另外一些醫師則是在嘗試,已經在部分患者身上使用,並持續觀察療程進展。在 First 產品線上,他們會把這些結合起來。因此我們看到我所稱的臨床滲透率顯著提升,因為我們現在能做那些在兩年前幾乎完全做不到的病例。
So I'd say the way to look at that is our teen first product, Invisalign First, being the most uptake and the fastest uptake, with mandibular advancement right behind it.
所以我會說,從這個角度來看,我們的青少年早期產品 Invisalign First 的採用度最高、導入速度也最快,而下顎前移緊隨其後。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Great. And any update on palate expansion?
很好。那顎腭擴弓方面有任何更新嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We have all the protocols. We know how to do it. We're trying to find a manufacturing capability that can scale with what we feel the needs are out there. That sounds trivial. But in a business like this where you have an incredible amount of volume you have to put through, we still have some work to do in that scale-up mode.
我們已經具備所有的治療流程(protocols),也知道怎麼做。我們正在尋找一種製造能力,能夠隨著我們認為市場需求所需的規模來擴張。這聽起來很瑣碎,但在這種必須處理極大量產能的業務中,我們在擴產(scale-up)模式上仍有一些工作要做。
Operator
Operator
Our next question comes from the line of Jeff Johnson with Baird.
下一個問題來自 Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
So a couple of clarifying questions here, if I could. One, I just want to go back to Jon Block's question on the North American number. It depends on how you read the sentence in your slide deck. Was North America up year-over-year in June? And then if I take your April, May, June comments, and May a little bit better, but June a significant better, it seems like June, on a kind of global revenue basis, had to have been down only about 10% to 20% or so. I don't know if you'll talk to that at all. But when I look at The Street down 20% in the 3Q, it seems like you should be pretty comfortable with The Street kind of at the $486 million revenue number, where it's at right now. So just any help you can give us, again, as we want to make sure we get kind of that 3Q at least ballpark accurate.
我這裡有幾個釐清性的問題,如果可以的話。第一個,我想回到 Jon Block 關於北美數字的問題。這取決於你如何解讀你們簡報中的那句話:北美在 6 月是否年增?另外,如果我把你對 4 月、5 月、6 月的評論串起來,5 月稍微好一些,但 6 月明顯更好,看起來 6 月以全球營收的角度,可能只下滑約 10% 到 20% 左右。我不確定你們是否會談這點。但當我看到市場共識(The Street)預期第三季下滑 20%,我覺得你們應該會相當有信心,市場共識目前約 4.86 億美元的營收數字是合理的。所以想請你們再提供一些協助,因為我們希望至少能把第三季的數字抓到大致準確的區間。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. Jeff, it's up year-over-year, not just quarter -- not yes, from a June standpoint, not just quarter-over-quarter, but June year-over-year. So it is a pretty strong signal.
是的,Jeff,6 月是年增,不只是季增——是的,從 6 月的角度來看,不只是相較上一季,而是 6 月相較去年同期也成長。所以這是一個相當強的訊號。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Yes. North America was up year-over-year in June.
是的,北美在 6 月是年增。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes.
是的。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Okay. And The Street being down 20% in the third quarter from a global revenue perspective, it sounds like your June kind of globally was probably down less than that 20%, if I connect the April, May, June comments. So just kind of your comfort at that $486 million number where The Street vet in 3Q, I know you're not guiding, but I would assume you don't have too many concerns on that number.
好的。那如果市場共識預期第三季以全球營收角度下滑 20%,聽起來你們 6 月在全球範圍內的下滑幅度可能小於 20%,如果我把你們對 4 月、5 月、6 月的評論連起來看的話。所以就市場共識第三季目前約 4.86 億美元的數字而言,我知道你們不提供財測,但我猜想你們對這個數字應該不會有太多疑慮。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We'll give you an A for trying. That was a good one, Jeff.
我們給你一個 A,因為你很努力。這題問得不錯,Jeff。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes, it's a good one, Jeff. No, we're not guiding, but we try to give you as much information. I know people are doing surveys and other work as well and you can help triangulate around it. But I just don't want to give out -- for the things that we've talked about, I don't want to give out future guidance.
是的,這題問得不錯,Jeff。不,我們不提供財測,但我們會盡量給你們更多資訊。我知道大家也在做調查和其他工作,你們也可以用這些來做交叉驗證、推算區間。但我只是不想——對於我們已經談到的事情,我不想提供未來指引。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
And Jeff, we're not being cute here. It's just -- it's hard to read signal through noise right now, okay? And that's what we're conveying to you, okay?
而且 Jeff,我們不是在故作玄虛。只是——現在真的很難在雜訊中讀出訊號,好嗎?這就是我們想傳達給你的,好嗎?
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Totally understood. Last question, just on the virtual tools. As some docs have come back, we're talking to them, they're saying, "Hey, I have had patients that I haven't seen in 3 months. They're still progressing well. They're maybe going to go to a Q3 month instead of an every 2-month follow-up schedule with their clear aligner patients." And that -- I mean it seems like, to me, we're getting chair time down on even some of these really messed up teen cases to 3 hours, 4 hours, virtual tools, maybe take that even lower over time. Just talk to the efficiencies and throughput advantages that's going to have versus braces. Isn't that going to be the real driver even more so than all this digital and what have you? It's just the efficiency improvements are getting so good here in clear aligners.
完全理解。最後一個問題,關於虛擬工具。隨著一些醫師回到診所,我們和他們交流時,他們說:「嘿,我有一些患者 3 個月沒見了,但進展仍然很好。他們對透明矯正患者的回診頻率,可能會從每 2 個月一次改成每 3 個月一次。」而且——我的意思是,對我來說,我們甚至在一些非常棘手的青少年病例上,把椅旁時間降到 3 小時、4 小時;虛擬工具也許會讓這個時間隨著時間推移更低。請談談相較於傳統牙套,這將帶來的效率與產能(throughput)優勢。這難道不會成為真正的驅動因素,甚至比所有這些數位化之類的更重要嗎?只是透明矯正的效率提升變得非常出色。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Yes. I'd say when you say all that digital, it's just that's what allows them to drive the efficiency you're talking about, Jeff. So when you have these kind of digital tools, they will allow you to monitor patients; to communicate with patients one-on-one; or any kind of AI, they can tell a patient if they're off track or on track. And we know that interaction also encourages patients with the most important variable in this line of treatment is compliance, making sure that they have their aligners intact. And if doctors are watching and we're keeping up in that sense, it helps also.
是的。我會說,當你提到「所有這些數位化」,其實正是這些東西讓他們能夠推動你所說的效率提升,Jeff。當你有這類數位工具時,它們能讓你監測患者、與患者一對一溝通;或透過任何 AI,告訴患者他們是否偏離計畫或仍在正軌。我們也知道,這種互動會鼓勵患者,因為在這種治療中最重要的變數是配合度(compliance),也就是確保他們確實佩戴矯正器。如果醫師在看、我們也能在這個意義上持續追蹤,這也會有幫助。
And so what doctors find out over time is that they can -- they don't have to see these patients like every 3 weeks, like they do with wires and brackets. They don't have the, obviously, the PPE and everything else associated with their staff and all working through these patients. And if a patient doesn't have to come in from a clear aligner standpoint, you either give them all their aligners upfront or you give them more aligners to allow them to continue their treatment without having an actual doctor's visit. So they're just tools that -- they're kind of tools that we use now and from a business standpoint that we have, but it is applied from the clinical standpoint to keep tracking of patients and to allow doctors to be more productive, for sure.
因此,醫師隨著時間會發現,他們可以——不必像使用鋼絲與托槽那樣每 3 週就見一次患者。顯然,他們也不需要面對與員工相關的 PPE 以及其他所有在看診流程中必須配套的事項。而從透明矯正的角度,如果患者不必進診所,你要嘛一開始就把所有矯正器一次交付給他們,要嘛就多給他們一些矯正器,讓他們在沒有實際回診的情況下也能繼續治療。所以這些工具——它們算是我們現在使用的工具,從商業角度我們也具備這些工具,但在臨床端的應用是用來持續追蹤患者,並讓醫師更具生產力,這點毫無疑問。
Operator
Operator
Our final question comes from the line of Richard Newitter with SVB Leerink.
我們最後一個問題來自 SVB Leerink 的 Richard Newitter。
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
I was just curious, the Switch Program that you guys are -- launched this quarter, has that been more effective in teens or adults? And then I have a follow-up.
我只是好奇,你們在本季推出的 Switch Program,到底在青少年或成人族群中哪一邊更有效?然後我還有一個追問。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. Rich, this is John. It's a program, as Joe had said, that we had -- we've had in Japan and other places as well. It's something that our doctors and many of their patients who were stuck in treatment and teeth were moving wanted to make a switch to this. It's not necessarily a teen versus adult. It's just patients who want to progress with treatment and didn't want the uncertainty of the current environment that they're in or future environment and went to their doctors and the doctors wanted to be able to switch them over, and we've made it so that they could do so.
是的,Rich,我是 John。這是一個計畫,正如 Joe 所說,我們之前在日本和其他地方也有——我們也有推出過。這是我們的醫師以及許多卡在治療中、牙齒正在移動的患者想要轉換到這個方案的一個做法。它不一定是青少年對成人的差別,而是那些想要讓治療繼續推進、且不想面對目前環境或未來環境不確定性的患者,他們去找醫師,而醫師也希望能把他們轉過來;我們讓他們可以這麼做。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I think, Rich, what you're hearing from both of us is, in this case, we're not quite sure exactly how many teens and adults were on the Switch Program. It's a good question. But you got to guess, statistically, the orthodontic market in the United States is 80% teens and 20% adults. So you can guess the majority of these switches were probably teens. But that's -- we're guessing, but we can get that data back to you.
我想,Rich,你從我們兩位這裡聽到的是:在這個案例中,我們不太確定到底有多少青少年與成人參與了 Switch Program。這是個好問題。但你可以推測,從統計上看,美國的齒顎矯正市場是 80% 青少年、20% 成人。所以你可以猜,大多數的轉換可能是青少年。不過那——我們是在猜,但我們可以把那個數據再回覆給你。
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
Richard S. Newitter - MD of Medical Supplies & Devices and Senior Research Analyst
Yes. And the bigger question there that I'm trying to get at, with some of the things that you're talking about in a post-COVID world and all of the benefits that now kind of pile onto aligners versus wires and brackets, I was trying to ask the question through the Switch Program to see if it -- to test my hypothesis. But it would seem that teens and the conversion with -- the conversation with adults and being able to get teens and the parents over the finish line, you have an added level of sell now. Is that what you're actually seeing in the marketplace? And is it fair to say that maybe COVID has resulted in the much-anticipated inflection point for teens? Is that fair?
是的。而我想追問的更大問題是,在後 COVID 的世界裡,結合你提到的一些事情,以及現在隱形矯正器相較於鋼線與托槽所累積的各種優勢,我是想透過 Switch Program 來提出這個問題,看看是否能——測試我的假設。但看起來在青少年方面,以及與成人的對話、並能讓青少年與家長最終拍板,你們現在多了一層更容易推動成交的力道。這是你們在市場上實際看到的情況嗎?而且是否可以說,COVID 可能帶來了青少年市場那個大家期待已久的拐點?這樣說公平嗎?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Well, it's fair that it's helped. I can't tell you that -- the inflection points here, but we certainly see a lot of uptake and interest in a digital workflow and our digital methodology in light of COVID-19. And our experience has been, when doctors can really convert most of their practice, and that's why ADAPT is, once you get over 50%, 60% digital, your practice has changed significantly. And consumers like it better, doctors tend to like it better, like we talked about, you have higher margin and also a dramatic increase, like 20% increase from a revenue standpoint. So yes, this is certainly -- COVID has certainly been a push for this.
嗯,說它有幫助是公平的。我無法告訴你——這裡的拐點是什麼,但我們確實看到在 COVID-19 的背景下,市場對數位化工作流程以及我們的數位方法論有很高的採用與興趣。依我們的經驗,當醫師能夠把他們的大部分診所流程轉為數位化——這也是 ADAPT 的重點——一旦你超過 50%、60% 的數位化,你的診所就會發生顯著改變。消費者更喜歡,醫師通常也更喜歡;如我們談到的,你的毛利更高,而且從營收角度也會有顯著提升,例如提升 20%。所以是的,這確實——COVID 的確推動了這件事。
We're cautious. We don't want to talk about a crisis that's just terrible for people actually enhancing our business. But the fact is, it does promote a workflow and a capability that's much more convenient at this point in time given the COVID threat.
我們很謹慎。我們不想談論一場對人們而言非常可怕的危機,卻說它在提升我們的業務。但事實是,鑑於目前的 COVID 威脅,它確實促進了一種在此時此刻更便利的工作流程與能力。
Operator
Operator
Our next question comes from the line of Michael Ryskin with Bank of America.
我們下一個問題來自美國銀行(Bank of America)的 Michael Ryskin。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
I have a couple of quick ones. In your prepared remarks, Joe and John, you've obviously talked about third quarter, how that's typically the strongest part of the teen season. Typically, you see the nice little bolus in the summer as everyone kind of stays home. I'm just curious, with the strength you saw in 2Q, do you think there could have been any sort of pull-forward in teens in the quarter, just looking at it for the last couple of months, everyone's in home anyway? So any expectations of maybe a little bit of a lull in 3Q? Or should we expect further pickup from current levels?
我有幾個很快的問題。在你們的事先準備發言中,Joe 和 John,你們顯然談到了第三季,通常那是青少年季節中最強的一段。一般來說,你們會在夏天看到一個不錯的小幅增量,因為大家大多待在家裡。我只是好奇,鑑於你們在第二季看到的強勁表現,你們是否認為本季青少年需求可能有任何提前拉動(pull-forward)的情況?畢竟過去幾個月大家本來就都在家。所以你們是否預期第三季可能會稍微放緩?還是我們應該預期在目前水準之上進一步回升?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I think, Michael, when you ask a question like that and you think of our business and how broad it is and global it is today, is there's just a lot of mitigating factors, right? So we can't tell you if there's a backlog of patients that have come in sooner or whatever. We just know it's teen season in the United States and as Canada and -- I mean, I'm sorry, in China, Canada also. And we're -- June was indicative of a good increase in the sense of teens looking for treatment, and we think that will continue.
Michael,我想當你問這樣的問題、並想到我們的業務如今有多廣、又是全球化的時候,會發現有很多緩衝因素,對吧?所以我們無法告訴你是否有病患提前進來、或是有什麼積壓之類的。我們只知道在美國現在是青少年季節,而加拿大以及——我是說,在中國、加拿大也是。而我們——6 月的情況顯示青少年尋求治療有不錯的增長,我們認為這會持續。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
Great. And then another quick one. I realize you don't want to talk about exit run rate or anything like that. But I think a lot of the assumptions go-forward are that there are no further lockdowns, there are no further sort of quarantine measures implemented. But I just want to ask, in recent weeks, with what's going on at Sunbelt, Texas, California, Florida, have you seen any fluctuation in volumes, any early indications there? I guess I'm kind of asking, on the one hand, you have full recovery of the economy, on the other hand, you have full lockdown, what if we're somewhere in the middle? Are you seeing any indications there?
很好。再一個快問。我知道你們不想談什麼退出時的運行率(exit run rate)之類的。但我想很多未來的假設是:不會再有進一步封城,也不會再實施進一步的隔離措施。不過我想問的是,最近幾週,隨著美國陽光帶(Sunbelt)、德州、加州、佛州的情況,你們是否看到量的波動,或任何早期跡象?我想問的是,一方面是經濟完全復甦,另一方面是完全封鎖,如果我們介於兩者之間,你們是否看到任何跡象?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
I would say no.
我會說沒有。
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Mike, I think we look at -- every area is different. We're seeing a different pace of recovery for the various regions and locations and practices. Some practices, they're open, but then somebody within the practice develops COVID and it shuts down. So it varies across. We're doing everything we can to make sure that those doctors have PPE, have promotions, have things in place to be able to help drive volume, but it's very dependent on those specific areas, not just in the U.S., but we're seeing this across the other regions as well.
Mike,我想我們看的是——每個地區都不一樣。我們看到不同區域、地點與診所的復甦速度不同。有些診所雖然開著,但診所內有人感染 COVID,就會關閉。所以各地差異很大。我們正在盡一切努力,確保那些醫師有 PPE(個人防護裝備)、有促銷方案、以及各種配套,來幫助帶動量,但這非常取決於那些特定地區,不只是在美國,我們在其他地區也看到同樣情況。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Mike, like -- it's back to Joe again, too. I just want you to know we have great enthusiasm for teens, and no matter where it is around the world, but we can't tell you if there's a surge of teen patients based on a lot of teens not being in school. We can't tell you if it's a backlog or whatever. But we can tell you we're enthusiastic about the season and that June was a good indication that it's heading in the right direction.
Mike——我再補充一下,這又回到 Joe。我只是想讓你知道,我們對青少年市場非常有熱情,不管在世界哪裡;但我們無法告訴你是否因為很多青少年沒去上學而出現青少年病患的激增。我們無法告訴你那是積壓需求或其他原因。但我們可以告訴你,我們對這個季節很有信心,而 6 月是一個很好的指標,顯示方向是對的。
Michael Leonidovich Ryskin - Associate
Michael Leonidovich Ryskin - Associate
Great. Can I ask a quick clarification? Okay. This has come up a dozen times in the past 5 minutes. Your response to Jeff's question on June, did you mean absolute case volume is up in North America in June or utilization is up in June?
很好。我可以快速釐清一下嗎?好。這在過去 5 分鐘已經出現十幾次了。你們回覆 Jeff 關於 6 月的問題時,你們的意思是北美 6 月的絕對病例量(case volume)上升,還是使用率(utilization)在 6 月上升?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Utilization.
使用率。
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
Utilization.
使用率。
Operator
Operator
Our final question comes from the line of Brandon Couillard with Jefferies.
我們最後一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
Joe or John, just a question on China. If you could speak to growth specifically in 2Q. I know it was still down year-over-year. And were there any other regions kind of outside the 3 that you listed, Japan, South Korea and Taiwan, that were ahead of kind of your internal expectations?
Joe 或 John,想問一個關於中國的問題。你們能否談談第二季的成長情況?我知道同比仍然是下滑的。另外,除了你們列出的三個地區——日本、南韓和台灣——是否還有其他地區的表現超出你們內部預期?
Joseph M. Hogan - President, CEO & Director
Joseph M. Hogan - President, CEO & Director
We -- no, I can't say that there was really. I mean we didn't talk a lot specifically about that. But Japan, Taiwan and Korea were exceptions because there were hardly a blip in the sense of what we saw in how they were affected with COVID. But really, every other country in APAC and most countries around the world, we said it fit for the expansion markets in Asia, even obviously, COVID was a big impact on them. I hope that answers your question.
我們——不,我不能說真的有。我們其實沒有特別針對那點談很多。但日本、台灣和韓國是例外,因為就我們看到的情況而言,它們受到 COVID 影響幾乎沒有什麼波動。但實際上,亞太地區(APAC)其他每個國家,以及全球大多數國家——我們說過,這也符合亞洲擴張市場的情況——顯然 COVID 對它們造成了很大影響。希望這回答了你的問題。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
I think so. John, any chance you could share with us the exocad contribution in the second quarter results? Or should we just wait for the Q for that?
我想是的。John,有沒有可能跟我們分享一下 exocad 在第二季結果中的貢獻?還是我們就等 Q(季報/10-Q)再看?
John F. Morici - CFO & Senior VP of Global Finance
John F. Morici - CFO & Senior VP of Global Finance
Yes. I think we talked about it at the end in the Scanner and Services segment that we have, and I think we would wait for the Q on that. But it's -- we acquired and it's part of our business, and we'll put more details into the Q.
是的。我想我們在最後談到掃描器與服務(Scanner and Services)部門時有提到,我想我們會等 Q(季報/10-Q)再提供。它——我們已收購,並且是我們業務的一部分,我們會在 Q 裡放入更多細節。
Shirley Stacy - VP of Corporate Communications & IR
Shirley Stacy - VP of Corporate Communications & IR
Well, I think that's the last question. So thank you, everyone, for joining us today. This concludes our conference call. If you have any follow-up questions, please follow up with Investor Relations. Have a great day.
好,我想這就是最後一個問題了。感謝各位今天加入我們。今天的電話會議到此結束。如有任何後續問題,請與投資人關係部門聯繫。祝各位有美好的一天。